Not recruiting
Psoriatic arthropathy
Not recruitingStudy on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors
Registered drug
Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors
Registered drug
- Disease:Psoriatic arthropathy
- Substances:ApremilastDeucravacitinib
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Apremilast



